All In Biotech

Drug Trial Radar · NCT00148798

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.

Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,861 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,861

Actual

Start

Oct 2004

Primary completion

Jul 2007

Study completion May 2012

Sponsor

Lead sponsor
Merck KGaA, Darmstadt, GermanyIndustry
Sponsor type
Industry
First posted
Sep 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

  • cetuximab + cisplatin + vinorelbineDrug

    cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.

  • cisplatin + vinorelbineDrug

    cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Time (OS)Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

Locations

118 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Adelaide, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Randwick, Australia

  • Research Site

    Sydney, Australia

  • Research Site

    Wodonga, Australia

  • Research Site

    Vienna, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Charleroi, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Stara Zagora, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Antofagasta, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Brno, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Brest, France

  • Research Site

    Caen, France

  • Research Site

    Grenoble, France

  • Research Site

    Marseille, France

  • Research Site

    Paris, France

  • Research Site

    Poitiers, France

  • Research Site

    Rennes, France

  • Research Site

    Rouen, France

  • Research Site

    Strasbourg, France

  • Research Site

    Augsburg, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Freiburg im Breisgau, Germany

  • Research Site

    Gauting, Germany

  • Research Site

    Göttingen, Germany

  • Research Site

    Großhansdorf, Germany

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.